Proteomic Methods in Neuropsychiatric Research
Paul C. Guest
ΠΌΠ°Ρ 2017. Β· Springer
Π-ΠΊΡΠΈΠ³Π°
370
Π‘ΡΡΠ°Π½ΠΈΡΠ°
reportΠΡΠ΅Π½Π΅ ΠΈ ΡΠ΅ΡΠ΅Π½Π·ΠΈΡΠ΅ Π½ΠΈΡΡ Π²Π΅ΡΠΈΡΠΈΠΊΠΎΠ²Π°Π½Π΅ Β Π‘Π°Π·Π½Π°ΡΡΠ΅ Π²ΠΈΡΠ΅
Π ΠΎΠ²ΠΎΡ Π΅-ΠΊΡΠΈΠ·ΠΈ
Due to continuous technical developments and new insights into the high complexity of neurological diseases, there is an increasing need for the application of proteomic technologies which can yield potential biomarker readouts for improved clinical management as well as for the development of new drugs by struggling pharmaceutical companies. This book describes the step-by-step use of proteomic methods such as two-dimensional gel electrophoresis, multiplex immunoassay, liquid chromatography mass spectrometry (LC-MS) and selective reaction monitoring MS, to increase our understanding of these diseases, with the ultimate aim of improving patient care.
The volume will be of high interest to clinical scientists, physicians and pharmaceutical company scientists as it gives insights into the latest technologies enabling the revolution of personalized medicine. It is of direct interest to both technical and bench biomarker scientists as it gives step by step instructions on how to carry out each of the protocols. It is also of interest to researchers as each technique will be presented in the context of a specific neurological disorder, including Alzheimer's disease, multiple sclerosis, autism spectrum disorders, schizophrenia, major depressive disorder and bipolar disorder.
Finally, it will also highlight the future research efforts in this field, which are endeavoring to convert proteomic platforms to the form of hand held devices which can be used in a point of care setting and return diagnostic results within the timeframe of a visit to the general practitioner.
The volume will be of high interest to clinical scientists, physicians and pharmaceutical company scientists as it gives insights into the latest technologies enabling the revolution of personalized medicine. It is of direct interest to both technical and bench biomarker scientists as it gives step by step instructions on how to carry out each of the protocols. It is also of interest to researchers as each technique will be presented in the context of a specific neurological disorder, including Alzheimer's disease, multiple sclerosis, autism spectrum disorders, schizophrenia, major depressive disorder and bipolar disorder.
Finally, it will also highlight the future research efforts in this field, which are endeavoring to convert proteomic platforms to the form of hand held devices which can be used in a point of care setting and return diagnostic results within the timeframe of a visit to the general practitioner.
ΠΡΠ΅Π½ΠΈΡΠ΅ ΠΎΠ²Ρ Π΅-ΠΊΡΠΈΠ³Ρ
ΠΠ°Π²ΠΈΡΠ΅ Π½Π°ΠΌ ΡΠ²ΠΎΡΠ΅ ΠΌΠΈΡΡΠ΅ΡΠ΅.
ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ΅ ΠΎ ΡΠΈΡΠ°ΡΡ
ΠΠ°ΠΌΠ΅ΡΠ½ΠΈ ΡΠ΅Π»Π΅ΡΠΎΠ½ΠΈ ΠΈ ΡΠ°Π±Π»Π΅ΡΠΈ
ΠΠ½ΡΡΠ°Π»ΠΈΡΠ°ΡΡΠ΅ Π°ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΡΡ Google Play ΠΊΡΠΈΠ³Π΅ Π·Π° Android ΠΈ iPad/iPhone. ΠΡΡΠΎΠΌΠ°ΡΡΠΊΠΈ ΡΠ΅ ΡΠΈΠ½Ρ
ΡΠΎΠ½ΠΈΠ·ΡΡΠ΅ ΡΠ° Π½Π°Π»ΠΎΠ³ΠΎΠΌ ΠΈ ΠΎΠΌΠΎΠ³ΡΡΠ°Π²Π° Π²Π°ΠΌ Π΄Π° ΡΠΈΡΠ°ΡΠ΅ ΠΎΠ½Π»Π°ΡΠ½ ΠΈ ΠΎΡΠ»Π°ΡΠ½ Π³Π΄Π΅ Π³ΠΎΠ΄ Π΄Π° ΡΠ΅ Π½Π°Π»Π°Π·ΠΈΡΠ΅.
ΠΠ°ΠΏΡΠΎΠΏΠΎΠ²ΠΈ ΠΈ ΡΠ°ΡΡΠ½Π°ΡΠΈ
ΠΠΎΠΆΠ΅ΡΠ΅ Π΄Π° ΡΠ»ΡΡΠ°ΡΠ΅ Π°ΡΠ΄ΠΈΠΎ-ΠΊΡΠΈΠ³Π΅ ΠΊΡΠΏΡΠ΅Π½Π΅ Π½Π° Google Play-Ρ ΠΏΠΎΠΌΠΎΡΡ Π²Π΅Π±-ΠΏΡΠ΅Π³Π»Π΅Π΄Π°ΡΠ° Π½Π° ΡΠ°ΡΡΠ½Π°ΡΡ.
Π-ΡΠΈΡΠ°ΡΠΈ ΠΈ Π΄ΡΡΠ³ΠΈ ΡΡΠ΅ΡΠ°ΡΠΈ
ΠΠ° Π±ΠΈΡΡΠ΅ ΡΠΈΡΠ°Π»ΠΈ Π½Π° ΡΡΠ΅ΡΠ°ΡΠΈΠΌΠ° ΠΊΠΎΡΠ΅ ΠΊΠΎΡΠΈΡΡΠ΅ Π΅-ΠΌΠ°ΡΡΠΈΠ»ΠΎ, ΠΊΠ°ΠΎ ΡΡΠΎ ΡΡ Kobo Π΅-ΡΠΈΡΠ°ΡΠΈ, ΡΡΠ΅Π±Π° Π΄Π° ΠΏΡΠ΅ΡΠ·ΠΌΠ΅ΡΠ΅ ΡΠ°ΡΠ» ΠΈ ΠΏΡΠ΅Π½Π΅ΡΠ΅ΡΠ΅ Π³Π° Π½Π° ΡΡΠ΅ΡΠ°Ρ. ΠΡΠ°ΡΠΈΡΠ΅ Π΄Π΅ΡΠ°ΡΠ½Π° ΡΠΏΡΡΡΡΠ²Π° ΠΈΠ· ΡΠ΅Π½ΡΡΠ° Π·Π° ΠΏΠΎΠΌΠΎΡ Π΄Π° Π±ΠΈΡΡΠ΅ ΠΏΡΠ΅Π½Π΅Π»ΠΈ ΡΠ°ΡΠ»ΠΎΠ²Π΅ Ρ ΠΏΠΎΠ΄ΡΠΆΠ°Π½Π΅ Π΅-ΡΠΈΡΠ°ΡΠ΅.
